News | June 01, 2009

Study Shows vProtect Luminal Shield Stabilizes Vulnerable Plaque

June 1, 2009 - Six months after placement of a vProtect Luminal Shield to treat a "vulnerable plaque,” a follow-up exam revealed reduced plaque burden and reduced stenosis in the target vessel.

The exam was part of the SECRITT I trial, a randomized study designed to evaluate the vProtec Luminal Shield as a prophylactic treatment for nonflow-limiting vulnerable plaques. The trial is sponsored and conducted by Erasmus University in Rotterdam. The six-month follow-up exam was performed May 20 by an interventional cardiology team led by Dr. Patrick Serruys, the principal investigator for the SECRITT I study. Evelyn Regar, M.D., Ph.D., moderated the case at the EuroPCR congress in Barcelona.

The vProtect Luminal Shield is manufactured by Prescient Medical, which plans to pursue a vulnerable plaque indication in the future.

The patient, a 75-year-old woman, was treated six months earlier for a culprit lesion in the left anterior descending coronary artery. At that time the SECRITT investigators, using a combination of imaging techniques, also located a vulnerable plaque in the patient's left circumflex artery. The lesion was unremarkable by angiography (37 percent stenosis); such lesions are usually not treated, even though vulnerable plaques are prone to rupture with potentially fatal consequences. A 3.5 mm vProtect Luminal Shield was placed in the vessel (reference vessel diameter 2.74 mm), resulting in a post-procedural stenosis of 30 percent.

The six-month angiographic follow-up exam was performed per study protocol using a variety of imaging techniques: multislice CT, intravascular ultrasound (IVUS), IVUS-virtual histology (IVUS-VH), angiography, and optical coherence tomography (OCT). Additional details on the SECRITT I study methodology can be found in a case study published recently in Nature Reviews Cardiology (Volume 6, May 2009).

The follow-up exam indicated the self-expanding vProtect Luminal Shield had stabilized the vulnerable lesion while gently expanding over time. Imaging studies revealed that the residual stenosis in the area of the lesion improved from 30 percent to just 5 percent (measured by quantitative angiography). The shield was covered by a thin layer of healthy tissue with an average thickness of 80-110 microns.

“These results are comparable to what is seen with drug-eluting stents in terms of thickness. We did not see a significant hyperplastic injury response,” said Gary Tearney, M.D., Ph.D., cardiac pathologist, associate professor of pathology at Harvard University and the Wellman Center for Photomedicine. “The Shield appears to be perfectly designed for just this type of lesion-since it’s self-expanding, there is less chance of rupturing the plaque.”

For more information: www.prescientmedical.com

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices | October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices | September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices | September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices | August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices | April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices | March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices | September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices | September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices | June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init